According to a new report published by Introspective Market Research, titled, Multiple Sclerosis Therapeutics Market by Drug Class, Route of Administration, and Region, The Global Multiple Sclerosis Therapeutics Market Size Was Valued at USD 26.30 Billion in 2023 and is Projected to Reach USD 44.80 Billion by 2032, Growing at a CAGR of 6.10 %.
The global multiple sclerosis (MS) therapeutics market is evolving rapidly as advances in disease-modifying therapies (DMTs) and improved diagnostic capabilities expand treatment options for a larger patient pool. MS, a chronic autoimmune condition affecting the central nervous system, leads to progressive disability in many patients if untreated. Therapeutics aimed at slowing disease progression, reducing relapse frequency, and managing symptoms have become core to patient care in this space.
Compared to older general immunosuppressant treatments, modern MS therapeutics offer more targeted mechanisms of action, improved efficacy and better patient convenience—such as oral drugs, less frequent dosing, and fewer side effects. Healthcare providers are increasingly moving toward these advanced options, driving broader adoption globally.
As awareness of MS rises and healthcare infrastructure in emerging regions strengthens, the demand for effective therapeutics grows. The introduction of novel therapies, expanding insurance coverage, and growing patient diagnosis rates are all contributing to the market’s upward trajectory.
The Multiple Sclerosis Therapeutics Market is segmented into Drug Class, Route of Administration, and Region. By Drug Class, the market is categorized into (Immunomodulators, Immunosuppressants, Monoclonal Antibodies, Others). By Route of Administration, the market is categorized into (Injectable, Oral, Infusion). By Region, the market is categorized into (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa).
A fundamental growth driver in the multiple sclerosis therapeutics market is the increasing global prevalence and diagnosis of MS, coupled with rising patient awareness and improved access to healthcare. As more patients are identified earlier in their disease course, the demand for therapeutic interventions—especially those that modify disease progression—grows significantly. In parallel, pharmaceutical innovation is enabling the development of therapies with improved safety profiles and convenience, which encourages greater uptake among clinicians and patients alike.
One significant market opportunity lies in the development and commercialisation of next-generation therapies targeting progressive forms of MS and unmet patient segments. Many patients with secondary-progressive or primary-progressive MS remain underserved by current treatments. The pipeline of novel agents—such as BTK inhibitors and newer monoclonal antibodies—provides an opening to capture this unmet need. Additionally, expansion into emerging markets, where diagnosis rates and treatment access are rising, offers substantial growth potential for therapeutics providers.
Multiple Sclerosis Therapeutics Market, Segmentation
The Multiple Sclerosis Therapeutics Market is segmented on the basis of Drug Class, Route of Administration, and Region.
Drug Class
The Drug Class segment is further classified into Immunomodulators, Immunosuppressants, Monoclonal Antibodies, and Others. Among these, the Immunosuppressants sub-segment accounted for the highest market share in 2023. This dominance is attributed to their broad application in relapsing-remitting MS, well-established clinical safety profiles, and wide adoption across geographies. They allow clinicians to manage immune activity and reduce relapse rates in large patient populations, giving them a strong position in the therapeutic mix.
Route of Administration
The Route of Administration segment is further classified into Injectable, Oral, and Infusion. Among these, the Injectable sub-segment accounted for the highest market share in 2023. Many established MS therapies employ injectable administration, offering proven efficacy and clinician familiarity. While oral and infusion routes grow in acceptance, the injectable format remains preferred due to long-standing use, ease of administration in clinics and coverage in treatment protocols.
Some of The Leading/Active Market Players Are-
- Biogen (USA)
- Novartis AG (Switzerland)
- Roche Holding AG (Switzerland)
- Sanofi S.A. (France)
- Merck?&?Co.,?Inc. (USA)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Johnson?&?Johnson Services,?Inc. (USA)
- Takeda Pharmaceutical Company Limited (Japan)
- BTG?plc (UK)
- Bayer?AG (Germany)
- other active players.
Key Industry Developments
-
In September 2024, Sanofi announced that its drug candidate Tolebrutinib (a BTK inhibitor) delayed the progression of a progressive form of MS by 31%. This milestone represents a major step in targeting previously difficult-to-treat MS populations and signals enhanced competition in the MS therapeutics space. The result supports Sanofi’s push to diversify its MS portfolio as older products face patent expiry and biosimilar competition.
- In April 2025, Ocrevus (by Roche) reported that a high-dose trial failed to show added benefit over the standard dosing in relapsing MS, underscoring strategic challenges in expanding the use of existing therapies.The outcome may reshape how companies approach dosing optimisation, lifecycle management and pipeline innovation in the MS market. It also highlights how competitive dynamics and therapeutic efficacy concerns are focusing R&D towards novel mechanisms rather than incremental upgrades.
Key Findings of the Study
- Immunosuppressants dominate the drug class due to broad uptake and proven outcomes.
- Injectable therapies retain largest share in route of administration despite growth in orals and infusions.
- North America remains the largest regional market, with Asia-Pacific growing fastest.
- Rising diagnosis rates and patient awareness are key growth drivers.
- Addressing progressive MS and entering emerging markets stand out as future opportunities.
